Mardi Dier - Mar 11, 2024 Form 3 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
SVP and CFO
Signature
/s/ Mardi Dier
Stock symbol
MDGL
Transactions as of
Mar 11, 2024
Transactions value $
$0
Form type
3
Date filed
3/21/2024, 04:30 PM
Previous filing
Jun 21, 2023
Next filing
Jun 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MDGL Common Stock 8.88K Mar 11, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MDGL Stock Option (Right to Buy) Mar 11, 2024 Common Stock 13.4K $251.63 Direct F2
holding MDGL Market Stock Unit Mar 11, 2024 Common Stock 8.88K Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units, which vest as to 25% of the shares on each of March 1, 2025, March 1, 2026, March 1, 2027 and March 1, 2028, provided the Reporting Person continues in service with the Issuer on each such date.
F2 The option vests as to 25% of the shares on the first anniversary of the date of grant (March 1, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.
F3 Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026.

Remarks:

Exhibit 24: Power of Attorney No securities are beneficially owned.